Tag: Anti-cancer agent

BARCELONA – Lutetium octreotate (OCLU), a targeted radionuclide, nearly doubles 12-month progression-free survival (PFS) compared to sunitinib in patients with advanced inoperable pancreatic cancer, researchers say has reported. The findings…

Rising costs are hitting patients hard. Her $2,000 cap on CMS price negotiations and Part D copayments should benefit many patients covered by Medicare. Oncology drugs are an increasingly large…